Insider Buying: MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Director Acquires 22,133 Shares of Stock

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA - Get Free Report) Director Cristian Luput acquired 22,133 shares of MAIA Biotechnology stock in a transaction dated Friday, November 1st. The shares were purchased at an average price of $2.51 per share, for a total transaction of $55,553.83. Following the completion of the transaction, the director now directly owns 389,483 shares in the company, valued at approximately $977,602.33. The trade was a 0.00 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

MAIA Biotechnology Price Performance

MAIA traded up $0.13 on Monday, hitting $2.88. 88,499 shares of the company were exchanged, compared to its average volume of 284,593. MAIA Biotechnology, Inc. has a 12 month low of $0.82 and a 12 month high of $5.99. The firm has a market cap of $68.86 million, a price-to-earnings ratio of -1.77 and a beta of 0.32.

MAIA Biotechnology (NYSEAMERICAN:MAIA - Get Free Report) last posted its quarterly earnings results on Friday, August 9th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.16. As a group, sell-side analysts anticipate that MAIA Biotechnology, Inc. will post -1.25 EPS for the current year.

Institutional Investors Weigh In On MAIA Biotechnology

Institutional investors and hedge funds have recently bought and sold shares of the business. Virtu Financial LLC purchased a new position in shares of MAIA Biotechnology in the 1st quarter valued at approximately $71,000. Mather Group LLC. lifted its stake in shares of MAIA Biotechnology by 50,150.0% in the 2nd quarter. Mather Group LLC. now owns 12,060 shares of the company's stock valued at $41,000 after purchasing an additional 12,036 shares during the period. Finally, Ground Swell Capital LLC bought a new position in MAIA Biotechnology during the 2nd quarter valued at approximately $56,000. Hedge funds and other institutional investors own 5.65% of the company's stock.

MAIA Biotechnology Company Profile

MAIA Biotechnology, Inc, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.